An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin with Pembrolizumab vs Pembrolizumab Monotherapy as First-Line Treatment in PD-L1 High Advanced NSCLC (BE6A LUNG-02)